ARCT - Re-enter in the 30's. 34-37 seems to be my gate with this one.
The ol' "buy the rumor, sell the news" strikes again.
Or, today is last day to sell for 2020 taxes -- Dump day.
Take your pick.
It's a pandemic market and more crazy and unexpected things to come.
Remember, ARCT has a lot more to offer than just COVID solutions.
Their tech enables many other biotech companies delivery and replication methods.
ARCT has established a 52-wk high of $130.
Many think it will go past that.
The ol' "buy the rumor, sell the news" strikes again.
Or, today is last day to sell for 2020 taxes -- Dump day.
Take your pick.
It's a pandemic market and more crazy and unexpected things to come.
Remember, ARCT has a lot more to offer than just COVID solutions.
Their tech enables many other biotech companies delivery and replication methods.
ARCT has established a 52-wk high of $130.
Many think it will go past that.
" faber est suae quisque fortunae " The above is for informational purposes only, responsibility for all trading decisions lies solely with the reader.
Recent ARCT News
- Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference • Business Wire • 05/26/2026 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:14:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:08:19 PM
- Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress • Business Wire • 05/07/2026 08:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/07/2026 07:37:51 PM
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 • Business Wire • 04/27/2026 08:01:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:05:10 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • InvestorsHub NewsWire • 04/20/2026 01:00:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/26/2026 07:56:44 PM
- Arcturus Therapeutics to Attend Upcoming Investor Conference • Business Wire • 03/05/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:05:54 PM
- Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress • Business Wire • 03/03/2026 09:01:00 PM
- Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 • Business Wire • 02/17/2026 09:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/03/2026 04:27:14 PM
- Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/08/2026 10:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/30/2025 09:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2025 01:30:40 PM
- Arcturus Therapeutics to Attend Upcoming Investor Conference • Business Wire • 11/24/2025 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:25:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 09:09:10 PM
- Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress • Business Wire • 11/10/2025 09:01:00 PM
- Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm • PR Newswire (US) • 11/10/2025 07:40:00 PM
- Arcturus Therapeutics to Attend Upcoming Investor Conferences • Business Wire • 11/04/2025 09:01:00 PM
